Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Massachusetts General Hospital
With
Brigham and Women's Hospital
Dana-Farber Cancer Institute
American Society of Clinical Oncology
* Each participant will receive a single dose of zoledronic acid intravenously after the screening procedures.
* Participants will then return to the clinic once every month for 6 months and have the following tests and procedures performed: Medical history update; physical exam; ECOG (Eastern Cooperative Oncology Group) Performance Status; blood tests; and urine tests.
* After 6 months there will be an end of study visit, where the following procedures will take place: medical history update; bone marrow aspirate and biopsy; skeletal survey.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women 18 years of age or older
Confirmed diagnosis of multiple myeloma(MM) by Durie and Dalmon staging criteria on IV bisphosphonate therapy with either pamidronate or zoledronic acid for 8-12 months
MM patients in either CR (complete response) or PR (partial response) by EBMT criteria
ECOG Performance Status of 0-2
You may not be if
MM patients on active anti-MM therapy (maintenance regimens allowed)
Renal failure with serum creatinine \>2mg/dL and/or creatinine clearance of \<30ml/min
Relapsed, refractory or progressive disease
Any condition or situation that, in the opinion of the investigator, may put the subject at significant risk, confound the results of the study, or interfere significantly with the subject's participation in the study
Hypersensitivity or any contraindication to a single dose of zoledronic acid
